Trial intelligence / Profile preview

Phase II Randomised Double-Blind Placebo-Controlled Study of AZD9668 in Cystic Fibrosis

2008-001530-27Phase 2Completed

Sponsor
AstraZeneca
Start
Apr 2008
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing AZD9668 arm with Placebo arm (2 arms). Primary endpoints: Absolute neutrophil count in sputum and Differential neutrophil cell count in sputum. Started Apr 2008; status: completed.

02

Drugs

alvelestat
03

Conditions

cystic fibrosis (CF)

Beyond the preview

Go deeper on 2008-001530-27.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-001530-27.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call